{
    "info": {
        "nct_id": "NCT03276572",
        "official_title": "Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer",
        "inclusion_criteria": "1. Histologically or cytologically confirmed adenocarcinoma of prostate\n2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:\n\n   1. PSA progression\n   2. Objective radiographic progression in soft tissue\n   3. New bone lesions\n3. ECOG performance status of 0-2\n4. Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.\n5. Have previously been treated with at least one of the following:\n\n   1. Androgen receptor signaling inhibitor (such as enzalutamide)\n   2. CYP 17 inhibitor (such as abiraterone acetate)\n6. Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.\n7. Age > 18 years\n8. Patients must have normal organ and marrow function as defined below:\n\n   1. Absolute neutrophil count >2,000 cells/mm3\n   2. Hemoglobin ≥9 g/dL\n   3. Platelet count >150,000 x 109/microliter\n   4. Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault\n   5. Serum total bilirubin <1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal\n   6. Serum AST and ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases (in both circumstances, bilirubin must meet entry criteria)\n9. Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1 or current enrollment in oncologic investigational drug or device study\n2. Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1 or current enrollment in investigational oncology drug or device study\n3. Prior systemic beta-emitting bone-seeking radioisotopes\n4. Known active brain metastases or leptomeningeal disease\n5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of C1D1\n6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study\n7. Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1\n8. Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study.\n9. Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration\n10. Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.\n11. Known history of known myelodysplastic syndrome",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "9. Ability to understand and the willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.",
            "criterions": [
                {
                    "exact_snippets": "serum testosterone < 50 ng/dL",
                    "criterion": "serum testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "continuation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "LHRH analogue (agonist/antagonist)"
                            ]
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "if they have not undergone bilateral orchiectomy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients must have normal organ and marrow function as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Patients must have normal organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must have normal organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed adenocarcinoma of prostate",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of prostate",
                    "criterion": "adenocarcinoma of prostate",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Have previously been treated with at least one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Have previously been treated with at least one of the following",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment(s)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Objective radiographic progression in soft tissue",
            "criterions": [
                {
                    "exact_snippets": "Objective radiographic progression in soft tissue",
                    "criterion": "soft tissue disease",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "objective radiographic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine <1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min/1.73 m2"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Platelet count >150,000 x 109/microliter",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >150,000 x 109/microliter",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 150000,
                                "unit": "x 10^9/microliter"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Age > 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age > 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. New bone lesions",
            "criterions": [
                {
                    "exact_snippets": "New bone lesions",
                    "criterion": "bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "new presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count >2,000 cells/mm3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >2,000 cells/mm3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2000,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Androgen receptor signaling inhibitor (such as enzalutamide)",
            "criterions": [
                {
                    "exact_snippets": "Androgen receptor signaling inhibitor (such as enzalutamide)",
                    "criterion": "androgen receptor signaling inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "use of androgen receptor signaling inhibitor (such as enzalutamide)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. CYP 17 inhibitor (such as abiraterone acetate)",
            "criterions": [
                {
                    "exact_snippets": "CYP 17 inhibitor (such as abiraterone acetate)",
                    "criterion": "CYP 17 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "use or treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. ECOG performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Serum total bilirubin <1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin <1.5 x ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless due to Gilbert's syndrome in which case direct bilirubin must be normal",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Hemoglobin ≥9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. PSA progression",
            "criterions": [
                {
                    "exact_snippets": "PSA progression",
                    "criterion": "PSA progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Documented progressive metastatic CRPC",
                    "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progressive"
                        },
                        {
                            "requirement_type": "metastatic_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Have previously received taxane chemotherapy",
                    "criterion": "taxane chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "been determined to be ineligible for taxane chemotherapy by their physician",
                    "criterion": "taxane chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "ineligibility (physician determined)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refused taxane chemotherapy",
                    "criterion": "taxane chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "7. Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy for treatment of PC ≤4 weeks of Day 1 Cycle 1",
                    "criterion": "radiation therapy for treatment of prostate cancer (PC)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Day 1 Cycle 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known active brain metastases or leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Known active brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Known history of known myelodysplastic syndrome",
            "criterions": [
                {
                    "exact_snippets": "Known history of known myelodysplastic syndrome",
                    "criterion": "myelodysplastic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1 or current enrollment in investigational oncology drug or device study",
            "criterions": [
                {
                    "exact_snippets": "Use of investigational drugs ≤4 weeks or <5 half-lives of Cycle 1, Day 1",
                    "criterion": "use of investigational drugs",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "current enrollment in investigational oncology drug or device study",
                    "criterion": "current enrollment in investigational oncology drug or device study",
                    "requirements": [
                        {
                            "requirement_type": "enrollment status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of C1D1",
            "criterions": [
                {
                    "exact_snippets": "History of deep vein thrombosis ... within 1 month of C1D1",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "month"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pulmonary embolus within 1 month of C1D1",
                    "criterion": "pulmonary embolus",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "month"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.",
            "criterions": [
                {
                    "exact_snippets": "Currently active other malignancy other than non-melanoma skin cancer",
                    "criterion": "other malignancy (excluding non-melanoma skin cancer)",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy",
                    "criterion": "completion of necessary therapy for malignancy",
                    "requirements": [
                        {
                            "requirement_type": "completion status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "considered by their physician to be at less than 30% risk of relapse",
                    "criterion": "risk of malignancy relapse",
                    "requirements": [
                        {
                            "requirement_type": "risk percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
            "criterions": [
                {
                    "exact_snippets": "Having partners of childbearing potential",
                    "criterion": "partners' childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration",
                    "criterion": "use of acceptable birth control method",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the study",
                                "for 1 month after last study drug administration"
                            ]
                        },
                        {
                            "requirement_type": "acceptability",
                            "expected_value": "deemed acceptable by the principle investigator and chairperson"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1 or current enrollment in oncologic investigational drug or device study",
            "criterions": [
                {
                    "exact_snippets": "Implantation of investigational medical device ≤4 weeks of Cycle 1, Day 1",
                    "criterion": "implantation of investigational medical device",
                    "requirements": [
                        {
                            "requirement_type": "time since implantation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "current enrollment in oncologic investigational drug or device study",
                    "criterion": "enrollment in oncologic investigational drug or device study",
                    "requirements": [
                        {
                            "requirement_type": "current enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study",
            "criterions": [
                {
                    "exact_snippets": "serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems",
                    "criterion": "serious illness involving organ systems",
                    "requirements": [
                        {
                            "requirement_type": "organ systems involved",
                            "expected_value": [
                                "cardiac",
                                "respiratory",
                                "CNS",
                                "renal",
                                "hepatic",
                                "hematological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients on stable dose of bisphosphonates or Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication",
                    "criterion": "bisphosphonate or Denosumab therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy start time before treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT-assessment period of the study",
                    "criterion": "bisphosphonate or Denosumab therapy initiation during DLT-assessment period",
                    "requirements": [
                        {
                            "requirement_type": "initiation during DLT-assessment period",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior systemic beta-emitting bone-seeking radioisotopes",
            "criterions": [
                {
                    "exact_snippets": "Prior systemic beta-emitting bone-seeking radioisotopes",
                    "criterion": "prior treatment with systemic beta-emitting bone-seeking radioisotopes",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "6. Serum AST and ALT <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases (in both circumstances, bilirubin must meet entry criteria)",
            "criterions": [
                {
                    "exact_snippets": "Serum AST ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                    "criterion": "serum AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "in absence of liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum AST ... <5x ULN if due to liver metastases",
                    "criterion": "serum AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "if due to liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum ALT ... <3 x ULN in absence of liver metastases; <5x ULN if due to liver metastases",
                    "criterion": "serum ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "in absence of liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum ALT ... <5x ULN if due to liver metastases",
                    "criterion": "serum ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "if due to liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "in both circumstances, bilirubin must meet entry criteria",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "meets entry criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}